Acurx Receives USAN Approval of Non-proprietary Name Ibezapolstat for Its Phase 2 Novel, First-in-Class Antibiotic for C. difficile Infection | State | oleantimesherald.com
http://www.oleantimesherald.com/news/state/acurx-receives-usan-approval-of-non-proprietary-name-ibezapolstat-for/article_fae8ebe2-48ff-5609-abae-37ab670f9d0f.htmlAcurx Successfully Completes Ph1 Clinical Trial for ACX-362E in CDI
https://www.prnewswire.com/news-releases/acurx-successfully-completes-ph1-clinical-trial-for-acx-362e-in-cdi-300908613.htmlAcurx's Novel Lead Antibiotic Candidate Presented at Two Prominent International Scientific Conferences
https://www.prnewswire.com/news-releases/acurxs-novel-lead-antibiotic-candidate-presented-at-two-prominent-international-scientific-conferences-300930932.html